Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 14.4% in October

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 40,400 shares, a decrease of 14.4% from the September 30th total of 47,200 shares. Based on an average trading volume of 37,300 shares, the short-interest ratio is currently 1.1 days.

Entera Bio Stock Down 1.1 %

NASDAQ:ENTX opened at $1.86 on Tuesday. Entera Bio has a 52 week low of $0.52 and a 52 week high of $3.35. The stock has a market cap of $66.56 million, a price-to-earnings ratio of -6.64 and a beta of 1.57. The company’s 50 day moving average price is $1.85 and its 200-day moving average price is $1.95.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $0.06 million during the quarter. As a group, sell-side analysts anticipate that Entera Bio will post -0.23 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a research report on Monday, October 7th.

Institutional Trading of Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC bought a new position in Entera Bio Ltd. (NASDAQ:ENTX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.